Trial · NCT07235202
Registered outcomes17
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 17 of 17
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of participants who experience one or more dose-limiting toxicities (DLTs) | Approximately 12 months | |
| Primary | Maximum Tolerated Dose (MTD) of MR001 | Approximately 12 months | The maximum tolerated dose (MTD) of MR001 was assessed for QW dosing schedules |
| Primary | Incidence of Adverse Events (AEs) as Assessed by CTCAE v5.0 | Approximately 30 months | |
| Primary | Objective Response Rate (ORR) | Approximately 24 months | |
| Primary | Best Overall Response (BOR) | Approximately 24 months | |
| Primary | Disease control rate (DCR) | Approximately 24 months | |
| Secondary | Recommended Phase II Dose (RP2D) of MR001 in combination with standard chemotherapy regimens in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) | Approximately 12 months | |
| Secondary | Progressionfree survival (PFS) | Approximately 24 months | |
| Secondary | Overall survival (OS) | Approximately 30 months | |
| Secondary | Area Under the Plasma ConcentrationTime Curve (AUC) of MR001 | Predose and at designated timepoints in each cycle for approximately 18 months (each cycle = 2 weeks or 4 weeks) | |
| Secondary | Maximum Plasma Concentration (Cmax) of MR001 | Predose and at designated timepoints in each cycle for approximately 18 months (each cycle = 2 weeks or 4 weeks) | |
| Secondary | Half-life (T1/2) of MR001 | Predose and at designated timepoints in each cycle for approximately 18 months (each cycle = 2 weeks or 4 weeks) | |
| Secondary | Incidence of Antidrug Antibodies (ADA) to MR001 | Predose in every 4 cycles for approximately 18 months (each cycle = 2 weeks or 4 weeks) | |
| Secondary | Change from baseline at different time points for Th1 in plasma | Predose and at designated timepoints in each cycle for approximately 18 months (each cycle = 2 weeks or 4 weeks) | |
| Secondary | Change from baseline at different timepoints for Th2 in plasma | Predose and at designated timepoints in each cycle for approximately 18 months (each cycle = 2 weeks or 4 weeks) | |
| Secondary | Change from baseline at different timepoints for TGF-β1 in plasma | Predose and at designated timepoints in each cycle for approximately 18 months (each cycle = 2 weeks or 4 weeks) | |
| Secondary | Change from baseline at different time points for CD4 in plasma | Predose and at designated timepoints in each cycle for approximately 18 months (each cycle = 2 weeks or 4 weeks) |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07235202/registered